HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $425
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on United Therapeutics and increased the price target from $400 to $425, indicating a positive outlook for the company's stock.
October 31, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on United Therapeutics and increased the price target from $400 to $425, suggesting a positive outlook for the stock.
The increase in the price target from $400 to $425 by HC Wainwright & Co. reflects a positive sentiment towards United Therapeutics' future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100